Insider Selling: LeMaitre Vascular, Inc. (LMAT) Chairman Sells $156,184.96 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Chairman George W. Lemaitre sold 4,672 shares of LeMaitre Vascular stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $33.43, for a total value of $156,184.96. Following the completion of the sale, the chairman now owns 3,165,709 shares in the company, valued at approximately $105,829,651.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

LeMaitre Vascular opened at $34.40 on Friday, according to Marketbeat.com. LeMaitre Vascular, Inc. has a 12 month low of $33.59 and a 12 month high of $34.05. The firm has a market cap of $655.08 million, a P/E ratio of 38.54, a P/E/G ratio of 2.09 and a beta of 0.57.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, April 25th. The medical instruments supplier reported $0.19 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by ($0.02). LeMaitre Vascular had a return on equity of 16.66% and a net margin of 17.34%. The company had revenue of $25.99 million for the quarter, compared to analyst estimates of $26.42 million. During the same period in the previous year, the firm earned $0.16 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. analysts anticipate that LeMaitre Vascular, Inc. will post 1.08 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 7th. Investors of record on Tuesday, May 22nd will be paid a dividend of $0.07 per share. The ex-dividend date is Monday, May 21st. This represents a $0.28 annualized dividend and a yield of 0.81%. LeMaitre Vascular’s payout ratio is 32.56%.

A number of equities research analysts have recently weighed in on the company. BidaskClub raised LeMaitre Vascular from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. ValuEngine raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Wednesday, April 4th. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Wednesday, February 28th. Stifel Nicolaus cut LeMaitre Vascular from a “buy” rating to a “hold” rating and dropped their price objective for the company from $40.00 to $34.00 in a research note on Thursday, April 26th. Finally, Benchmark raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Thursday, April 26th. Six research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. LeMaitre Vascular presently has a consensus rating of “Hold” and a consensus price target of $35.33.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in LeMaitre Vascular by 2.9% during the 1st quarter. BlackRock Inc. now owns 2,331,839 shares of the medical instruments supplier’s stock worth $84,483,000 after purchasing an additional 65,903 shares in the last quarter. Conestoga Capital Advisors LLC boosted its position in shares of LeMaitre Vascular by 55.3% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,327,376 shares of the medical instruments supplier’s stock worth $42,264,000 after acquiring an additional 472,732 shares in the last quarter. Epoch Investment Partners Inc. boosted its position in shares of LeMaitre Vascular by 3.9% during the 1st quarter. Epoch Investment Partners Inc. now owns 771,339 shares of the medical instruments supplier’s stock worth $27,945,000 after acquiring an additional 28,627 shares in the last quarter. Allianz Asset Management GmbH boosted its position in shares of LeMaitre Vascular by 8.2% during the 4th quarter. Allianz Asset Management GmbH now owns 348,087 shares of the medical instruments supplier’s stock worth $11,083,000 after acquiring an additional 26,267 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of LeMaitre Vascular by 1.8% during the 1st quarter. Northern Trust Corp now owns 249,251 shares of the medical instruments supplier’s stock worth $9,030,000 after acquiring an additional 4,465 shares in the last quarter. 72.52% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply